Iguana Healthcare Management LLC boosted its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 20.0% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 30,000 shares of the medical equipment provider’s stock after buying an additional 5,000 shares during the period. Zimmer Biomet accounts for approximately 1.9% of Iguana Healthcare Management LLC’s holdings, making the stock its 18th biggest position. Iguana Healthcare Management LLC’s holdings in Zimmer Biomet were worth $3,513,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Bronfman E.L. Rothschild L.P. grew its position in shares of Zimmer Biomet by 25.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares in the last quarter. Bank of Nova Scotia Trust Co. purchased a new position in shares of Zimmer Biomet during the third quarter valued at about $112,000. FNY Managed Accounts LLC purchased a new position in shares of Zimmer Biomet during the third quarter valued at about $117,000. BB&T Investment Services Inc. purchased a new position in shares of Zimmer Biomet during the second quarter valued at about $144,000. Finally, Sandy Spring Bank grew its position in shares of Zimmer Biomet by 5.4% during the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 66 shares in the last quarter. Institutional investors and hedge funds own 86.24% of the company’s stock.
A number of brokerages have recently weighed in on ZBH. BMO Capital Markets restated a “buy” rating and set a $142.00 price objective on shares of Zimmer Biomet in a research report on Tuesday. TheStreet lowered Zimmer Biomet from a “b-” rating to a “c+” rating in a research report on Friday, November 24th. Zacks Investment Research lowered Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, November 20th. Deutsche Bank upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price objective for the company in a research report on Tuesday, November 14th. Finally, Edward Jones upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Thursday, November 9th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $134.05.
Zimmer Biomet Holdings Inc (NYSE:ZBH) traded down $0.02 on Thursday, reaching $113.52. The company had a trading volume of 2,815,500 shares, compared to its average volume of 1,362,485. The stock has a market capitalization of $22,988.79, a price-to-earnings ratio of 14.07, a P/E/G ratio of 1.76 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 12 month low of $100.81 and a 12 month high of $133.49. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The company’s revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.79 EPS. analysts predict that Zimmer Biomet Holdings Inc will post 8.03 earnings per share for the current year.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.